The initial landmark studies by Druker et al. showed high response rates to Imatinib in patients with advanced CML [10] and those pretreated with IFN-α [10, 11]. This evidence concerns the gene IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive.